A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies

Inclusion Criteria: * ≥ 18 years of age; * Progressed during, refractory to, intolerant of, or ineligible for established therapy, or has a disease with no established therapy with the exception of expansion cohort of treatment naïve CLL patients; * An Eastern Cooperative Oncology Group (ECOG) score of 0 to 2. Exclusion Criteria: * Any previous treatment with a PI3K inhibitor (Escalation Phase only) or within 4 weeks of the start of IPI-145 administration (Expansion Phase); * Patients with overt leptomeningeal leukemia or CNS lymphoma; * Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2.5 x upper limit of normal (ULN); direct bilirubin \>1.5 x ULN; * Inadequate renal function defined by serum creatinine \> 1.5 x ULN